ES2088838T1 - Secuencias de consenso kozak completamente debilitadas para expresion de mamiferos. - Google Patents

Secuencias de consenso kozak completamente debilitadas para expresion de mamiferos.

Info

Publication number
ES2088838T1
ES2088838T1 ES94901599T ES94901599T ES2088838T1 ES 2088838 T1 ES2088838 T1 ES 2088838T1 ES 94901599 T ES94901599 T ES 94901599T ES 94901599 T ES94901599 T ES 94901599T ES 2088838 T1 ES2088838 T1 ES 2088838T1
Authority
ES
Spain
Prior art keywords
atg
expression
disclosed
nucleotide
pyxx
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES94901599T
Other languages
English (en)
Other versions
ES2088838T3 (es
Inventor
Mitchell E Reff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idec Pharmaceuticals Corp
Original Assignee
Idec Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/147,696 external-priority patent/US5648267A/en
Application filed by Idec Pharmaceuticals Corp filed Critical Idec Pharmaceuticals Corp
Publication of ES2088838T1 publication Critical patent/ES2088838T1/es
Application granted granted Critical
Publication of ES2088838T3 publication Critical patent/ES2088838T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Image Analysis (AREA)

Abstract

SE DESCRIBEN AQUI SECUENCIAS KOZAK DE CONSENSO COMPLETAMENTE DETERIORADO QUE SON MAS TIPICAMENTE EMPLEADAS CON MARCADORES SELECCIONABLES DOMINANTES DE CINTAS TRANSCRIPCIONALES QUE SON UNA PARTE DE UN VECTOR DE PRESENTACION. ESTOS VECTORES SE EMPLEAN MAS TIPICAMENTE EN LA PRESENTACION DE PROTEINAS EN SISTEMAS DE PRESENTACION MAMIFERO. AQUI, SE DEFINE, DESCRIBE Y RECLAMA, UNA SECUENCIA "KOZAK DE CONSENSO COMPLETAMENTE DETERIORADO" QUE COMPRENDE LA SECUENCIA (I), DONDE: "X" ES UN NUCLEOTIDO SELECCIONADO ENTRE UN GRUPO QUE CONSISTE EN ADENINA (A), GUANINA (G), CITOSINA (C) O TIMINA (T) / URACILO (U); "PY" ES UN NUCLEOTIDO DE PIRIMIDINA, ES DECIR C O TU; "ATG" ES UN CODON CODIFICADO POR METIONINA DE ACIDO AMINO, EL LLAMADO CODON ESTRELLA; Y -3 Y +1 SON PUNTOS DE REFERENCIA DIRECCIONALES RESPECTO A ATG, ES DECIR -3 INDICA TRES NUCLEOTIDOS CORRIENTE ARRIBA DEL ATG Y +1 INDICA UN NUCLEOTIDO CORRIENTE ABAJO DEL ATG. ADEMAS SE DESCRIBEN LOS MARCADORES SELECCIONABLES DOMINANTES QUE COMPRENDEN ADEMAS REGIONES DE INSERCION INTRONICA ARTIFICIALES.
ES94901599T 1992-11-13 1993-11-12 Secuencias kozak de consenso totalmente alteradas destinadas a la expresion en los mamiferos. Expired - Lifetime ES2088838T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US97769192A 1992-11-13 1992-11-13
US977691 1992-11-13
US147696 1993-11-03
US08/147,696 US5648267A (en) 1992-11-13 1993-11-03 Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same

Publications (2)

Publication Number Publication Date
ES2088838T1 true ES2088838T1 (es) 1996-10-01
ES2088838T3 ES2088838T3 (es) 2004-01-01

Family

ID=26845148

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94901599T Expired - Lifetime ES2088838T3 (es) 1992-11-13 1993-11-12 Secuencias kozak de consenso totalmente alteradas destinadas a la expresion en los mamiferos.

Country Status (8)

Country Link
US (3) US5733779A (es)
EP (1) EP0669986B1 (es)
AT (1) ATE236987T1 (es)
CA (1) CA2149326C (es)
DE (2) DE69332859T2 (es)
DK (1) DK0669986T3 (es)
ES (1) ES2088838T3 (es)
PT (1) PT669986E (es)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6086527A (en) 1998-04-02 2000-07-11 Scimed Life Systems, Inc. System for treating congestive heart failure
CN100358577C (zh) 1999-05-07 2008-01-02 杰南技术公司 抗体在制备治疗哺乳动物自身免疫病的试剂中的用途
KR20040023565A (ko) * 2000-09-18 2004-03-18 아이덱 파마슈티칼즈 코포레이션 Ｂ 세포 고갈/면역조절 항체 조합을 이용한 자가면역질환의 치료를 위한 조합 요법
US20050144655A1 (en) * 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6972324B2 (en) * 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
ZA200508985B (en) * 2001-07-10 2006-07-26 Biogen Idec Inc Inhibition of apotosis process and improvement of cell performance
MXPA04004634A (es) 2001-11-16 2004-08-12 Idec Pharma Corp Expresion policistronica de anticuerpos.
AU2003213270A1 (en) * 2002-02-25 2003-09-09 Intronn, Inc. Trans-splicing mediated imaging of gene expression
US20040172667A1 (en) * 2002-06-26 2004-09-02 Cooper Richard K. Administration of transposon-based vectors to reproductive organs
US7527966B2 (en) 2002-06-26 2009-05-05 Transgenrx, Inc. Gene regulation in transgenic animals using a transposon-based vector
US20040235011A1 (en) * 2002-06-26 2004-11-25 Cooper Richard K. Production of multimeric proteins
SI1523496T1 (sl) 2002-07-18 2011-11-30 Merus B V Rekombinantno proizvajanje zmesi protiteles
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
EP1572994B1 (en) 2002-12-20 2007-02-21 Chromagenics B.V. Means and methods for producing a protein through chromatin openers that are capable of rendering chromatin more accessible to transcription factors
EP1596806A4 (en) * 2003-01-27 2007-08-29 Biogen Idec Inc COMPOSITIONS AND METHODS FOR TREATING CANCER USING IGSF9 AND LIV-1
EP2248899B8 (en) 2003-03-19 2015-07-15 Biogen MA Inc. NOGO receptor binding protein
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
NZ568403A (en) * 2003-05-09 2009-10-30 Univ Duke CD20-specific antibodies and methods of employing same
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
AU2004242614B2 (en) 2003-05-30 2011-09-22 Merus N.V. Fab library for the preparation of anti vegf and anti rabies virus fabs
EP1660654B1 (en) 2003-09-04 2011-11-09 Medarex, Inc. Expression vector
US8071364B2 (en) * 2003-12-24 2011-12-06 Transgenrx, Inc. Gene therapy using transposon-based vectors
ES2646560T3 (es) 2004-01-20 2017-12-14 Merus N.V. Mezclas de proteínas de unión
WO2006002437A2 (en) * 2004-06-24 2006-01-05 Biogen Idec Ma Inc. Treatment of conditions involving demyelination
JP5060293B2 (ja) 2004-08-03 2012-10-31 バイオジェン・アイデック・エムエイ・インコーポレイテッド 神経機能におけるｔａｊ
US8999667B2 (en) * 2004-11-08 2015-04-07 Chromagenics B.V. Selection of host cells expressing protein at high levels
PL1809750T3 (pl) * 2004-11-08 2012-08-31 Chromagenics Bv Selekcja komórki gospodarza eksprymującej białko na wysokich poziomach
CN101090968B (zh) * 2004-11-08 2011-10-26 科罗迈吉尼科斯公司 高水平表达蛋白质的宿主细胞的选择
US8039230B2 (en) * 2004-11-08 2011-10-18 Chromagenics B.V. Selection of host cells expressing protein at high levels
US20060195935A1 (en) 2004-11-08 2006-08-31 Chromagenics B.V. Selection of host cells expressing protein at high levels
KR20070100346A (ko) 2005-01-05 2007-10-10 바이오겐 아이덱 엠에이 인코포레이티드 크립토 결합 분자
KR101245462B1 (ko) 2005-07-08 2013-03-20 바이오겐 아이덱 엠에이 인코포레이티드 Ｓｐ35 항체 및 그의 용도
NZ568705A (en) 2005-11-04 2012-07-27 Biogen Idec Inc Methods for promoting neurite outgrowth and survival of dopaminergic neurons
CA2631181A1 (en) 2005-12-02 2007-06-07 Biogen Idec Ma Inc. Treatment of conditions involving demyelination
EP1806365A1 (en) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
HRP20151108T1 (xx) 2006-01-27 2015-11-20 Biogen Ma Inc. Antagonisti nogo-receptora
AU2007245164A1 (en) * 2006-03-28 2007-11-08 Biogen Idec Ma Inc. Anti-IGF-IR antibodies and uses thereof
EA017611B1 (ru) 2007-01-05 2013-01-30 Юнивэсэти Оф Цюрих Способ получения связывающей молекулы, специфичной к белку, ассоциированному с расстройством, или антитела или его связывающего фрагмента или по меньшей мере одной цепи иммуноглобулина, связывающих вышеуказанный белок (варианты), связывающая молекула, антитело, цепь иммуноглобулина или их связывающий фрагмент (варианты), антиген, полинуклеотид, вектор и клетка-хозяин, их включающие композиция и набор и способ диагностики или лечения неврологических расстройств посредством
SI2068887T1 (sl) 2007-01-09 2014-06-30 Biogen Idec Ma Inc. SP35 protitelesa in njihova uporaba
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
NZ578816A (en) 2007-02-02 2012-06-29 Biogen Idec Inc Use of semaphorin 6a for promoting myelination and oligodendrocyte differentiation
CA2697612A1 (en) * 2007-08-28 2009-03-12 Biogen Idec Ma Inc. Anti-igf-1r antibodies and uses thereof
CN101842116A (zh) * 2007-08-28 2010-09-22 比奥根艾迪克Ma公司 结合igf-1r多个表位的组合物
JP2011516549A (ja) * 2008-04-11 2011-05-26 バイオジェン アイデック マサチューセッツ インコーポレイテッド 抗ｉｇｆ−１ｒ抗体と他の化合物との治療的併用
DK2982695T3 (da) 2008-07-09 2019-05-13 Biogen Ma Inc Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
US9150880B2 (en) * 2008-09-25 2015-10-06 Proteovec Holding, L.L.C. Vectors for production of antibodies
US20100081789A1 (en) * 2008-09-25 2010-04-01 Cooper Richard K Novel Vectors for Production of Interferon
WO2010036978A2 (en) * 2008-09-25 2010-04-01 Transgenrx, Inc. Novel vectors for production of growth hormone
PL2370466T3 (pl) 2008-12-19 2015-12-31 Biogen Int Neuroscience Gmbh Ludzkie autoprzeciwciała anty-alfa-synukleina
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
JP2012514458A (ja) 2008-12-31 2012-06-28 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗リンホトキシン抗体
US9309519B2 (en) 2009-03-31 2016-04-12 Celltrion Inc. Method for selecting a high expression recombinant cell line
US9150881B2 (en) * 2009-04-09 2015-10-06 Proteovec Holding, L.L.C. Production of proteins using transposon-based vectors
US9212367B2 (en) * 2009-08-06 2015-12-15 Cmc Icos Biologics, Inc. Methods for improving recombinant protein expression
EP2533810B1 (en) 2010-02-10 2016-10-12 ImmunoGen, Inc. Cd20 antibodies and uses thereof
AU2011274423B2 (en) 2010-07-09 2016-02-11 Bioverativ Therapeutics Inc. Chimeric clotting factors
US20130295021A1 (en) 2010-10-11 2013-11-07 Feng Chen Human anti-tau antibodies
CN103380145B (zh) 2010-12-17 2016-10-12 生物控股有限公司 人类抗-sod1抗体
EP2723379B1 (en) 2011-06-23 2018-09-12 Biogen International Neuroscience GmbH Anti-alpha synuclein binding molecules
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
SG10201913376XA (en) 2012-04-20 2020-02-27 Merus Nv Methods and means for the production of ig-like molecules
EA030716B1 (ru) 2012-05-14 2018-09-28 Байоджен Ма Инк. Антагонисты lingo-2 для лечения заболеваний, в которых участвуют двигательные нейроны
CA2875247A1 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Chimeric clotting factors
EA201590709A1 (ru) 2012-10-09 2015-09-30 Байоджен Айдек Ма Инк. Комбинированная терапия и ее применение для лечения димиелинизирующих расстройств
SMT202000512T1 (it) 2012-12-21 2021-01-05 Biogen Int Neuroscience Gmbh Anticorpi anti-tau umani
WO2014102399A1 (en) 2012-12-31 2014-07-03 Neurimmune Holding Ag Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
LT2956477T (lt) 2013-02-15 2021-02-10 Bioverativ Therapeutics Inc. Optimizuotas faktoriaus viii genas
TWI745671B (zh) 2013-03-15 2021-11-11 美商百歐維拉提夫治療公司 因子ｉｘ多肽調配物
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
JP2017522886A (ja) 2014-07-29 2017-08-17 ニューリミューン ホールディング エイジー ヒト由来抗ハンチンチン（ｈｔｔ）抗体及びその使用
SG10201902850TA (en) 2014-09-30 2019-04-29 Neurimmune Holding Ag Human-derived anti-dipeptide repeats (dprs) antibody
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
MA40861A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
WO2016112270A1 (en) 2015-01-08 2016-07-14 Biogen Ma Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
MX2018001497A (es) 2015-08-03 2018-05-15 Bioverativ Therapeutics Inc Proteinas de fusion de factor ix y metodos para producirlas y usarlas.
KR20180118659A (ko) 2016-02-01 2018-10-31 바이오버라티브 테라퓨틱스 인크. 최적화된 viii 인자 유전자
CN109862911A (zh) 2016-07-13 2019-06-07 比奥根Ma公司 Lingo-1拮抗剂的剂量方案和用于治疗脱髓鞘病症的用途
WO2018102760A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
IL319473A (en) 2016-12-02 2025-05-01 Bioverativ Therapeutics Inc Methods for treating hemophilic arthritis using chimeric blood clotting factors
US20210238259A1 (en) 2017-01-31 2021-08-05 Bioverativ Therapeutics Inc. Factor ix fusion proteins and methods of making and using same
JP7374883B2 (ja) 2017-08-09 2023-11-07 バイオベラティブ セラピューティクス インコーポレイテッド 核酸分子およびその使用
JP7464530B2 (ja) 2018-03-28 2024-04-09 ブリストル－マイヤーズ スクイブ カンパニー インターロイキン－２／インターロイキン－２受容体アルファ融合タンパク質および使用方法
MX2020011312A (es) 2018-04-27 2021-03-26 Biogen Ma Inc Anticuerpo de repetición de dipéptidos (dpr) anti poliglicina-alanina (poli-ga) derivado de humanos.
LT3793588T (lt) 2018-05-18 2025-06-25 Bioverativ Therapeutics Inc. Hemofilijos a gydymo būdai
JP7457661B2 (ja) 2018-06-04 2024-03-28 バイオジェン・エムエイ・インコーポレイテッド 低減したエフェクター機能を有する抗ｖｌａ－４抗体
IL299333A (en) 2020-06-24 2023-02-01 Bioverativ Therapeutics Inc Methods for the purification of viral vectors
JP2024534124A (ja) 2021-08-23 2024-09-18 バイオベラティブ セラピューティクス インコーポレイテッド 逆位末端反復配列によるクローズドエンドｄｎａの作製
WO2023028456A1 (en) 2021-08-23 2023-03-02 Bioverativ Therapeutics Inc. Optimized factor viii genes
KR20240067122A (ko) 2021-09-30 2024-05-16 바이오버라티브 테라퓨틱스 인크. 감소된 면역원성을 갖는 인자 viii 폴리펩타이드를 암호화하는 핵산

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same

Also Published As

Publication number Publication date
US5733779A (en) 1998-03-31
DE669986T1 (de) 1996-10-10
EP0669986B1 (en) 2003-04-09
EP0669986A1 (en) 1995-09-06
US6159730A (en) 2000-12-12
DK0669986T3 (da) 2003-07-28
CA2149326C (en) 2007-04-17
ATE236987T1 (de) 2003-04-15
US6017733A (en) 2000-01-25
DE69332859D1 (de) 2003-05-15
DE69332859T2 (de) 2003-12-18
CA2149326A1 (en) 1994-05-26
ES2088838T3 (es) 2004-01-01
PT669986E (pt) 2003-08-29

Similar Documents

Publication Publication Date Title
ES2088838T1 (es) Secuencias de consenso kozak completamente debilitadas para expresion de mamiferos.
WO1994011523A3 (en) Fully impaired consensus kozac sequences for mammalian expression
Miyata et al. Nucleotide sequence divergence of mouse immunoglobulin gamma 1 and gamma 2b chain genes and the hypothesis of intervening sequence-mediated domain transfer.
WO1992001049A3 (en) Cd53 cell surface antigen and use thereof
AR056723A2 (es) Polipeptido purificado metodo para producirlo , metodo para identificarlo y/ o aislarlo composicion farmaceutica que lo comprende, secuencia de acidos nucleicos aislada que codifica dicho polipeptido, vector que contiene a dicha secuencia celula huesped transfectada por dicho vector, sonda nucleotid
AU658634B2 (en) Synthetic catalytic oligonucleotide structures containing modified nucleotides
ATE64151T1 (de) Rekombinante immunoglobulin-praeparate, verfahren zu ihrer herstellung, dna-sequenzen, expressionsvektoren und rekombinante wirkzellen hierfuer.
DK0597960T3 (da) Behandling af cellepopulationer
ATE275628T1 (de) Expressionssteigernde sequenzelemente (ease) für eukaryontische expressionssysteme
EP0330191A3 (en) DNA encoding CD40
ATE66693T1 (de) Rekombinante dns-sequenzen, diese enthaltende vektoren und verfahren zur verwendung derselben.
HUP9904203A2 (hu) Eljárás hosszú, ismétlődő DNS-szekvenciák stabil klónozására
Obaru et al. Cloning and sequence analysis of mRNA for mouse aspartate aminotransferase isoenzymes.
MX235300B (en) Resistance against nematodes and/or aphids
AU2890497A (en) Nucleoside derivatives with photolabile protective groups
BG100939A (bg) Алфа-1-антихимотрипсинови аналози имащи еластазна инхибираща активност
BR9407693A (pt) Sequência nucleotídica vetor composiçao farmacêutica utilizaçao do vetor e de um composto
Ogawa et al. Molecular cloning, sequence analysis, and expression in Escherichia coli of the cDNA for guanidinoacetate methyltransferase from rat liver.
ZA961349B (en) Amplifying sequences vectors comprising these sequences and their uses in compositions for the expression of nucleotide sequences in transfected cells therapeutic and vaccine applications
DE69233612D1 (de) Verfahren zur bildung einer strukturellen und funktionellen diversität in einer peptidsequenz
DE3688383D1 (de) Rekombinantes vektorsystem fuer metalloproteinase-inhibitorsequenz und dessen verwendung und herstellung nach dem rekombinant-dns-verfahren.
ATE215123T1 (de) Or-1, ein wais-rezeptor der nuklearen rezeptoren familie
DK0981537T3 (da) Smitsom klon af humant parainfluenzavirus type 3
ATE281523T1 (de) Acarbose-biosynthesegene aus actinoplanes sp., verfahren zu ihrer isolierung sowie ihrer verwendung
Goldfarb et al. Transcription in vitro of an isolated fragment of bacteriophage T4 genome